Aggressive Patents Should Have Senior Management Support, Pfizer Attorney Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Management should "buy-in" before controversial patents that could delay generic entry are listed, Pfizer Senior Patent Counsel Pokras says. Pokras suggests that some people, including state prosecutors, would not see the "connection" between a patent on a metered dose device and the drug product.